SCHEMBL830341

SCHEMBL830341

O=c1[nH]c2cc(Cl)ccc2cc1S(=O)(=O)Cc1ccc(Cl)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.48
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
IDH1 O75874 1/20 0.40
AKR1B1 P15121 1/20 0.38
F11 P03951 1/20 0.38
CA5A P35218 1/20 0.37
PARP1 P09874 1/20 0.37
ERCC1 P07992 1/20 0.36
ERCC4 Q92889 1/20 0.36
KMT2A Q03164 1/20 0.36
ALOX15 P16050 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830692 0.90 CDK5 (0.44) DAOIDH1KMT2AALOX15
SCHEMBL829565 0.84 DAO (0.50) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL830417 0.83 DAO (0.55) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL830098 0.79 DAO (0.43) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL829211 0.78 DAO (0.60) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL831065 0.78 MGAM (0.38) DAOCA5APARP1
SCHEMBL831121 0.77 PDGFRB (0.45) DAOKMT2A
SCHEMBL831381 0.76 TXNRD1 (0.40) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL831473 0.74 GRM4 (0.39) ERCC1ERCC4KMT2A
SCHEMBL830356 0.73 MAPT (0.43) DAOKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP claimed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 DAO 3359/4885GRIN2D 2104/4885GRIN3B 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.